Steven Ramael

Steven has been involved in early clinical development since 2001. From 2013 to 2018, Steven served as Medical Director of Ogeda (acquired by Astellas) and led the clinical development of the NK3 antagonist fezolinetant. Previously, Steven worked as an Investigator at SGS Life Science Services conducting over 60 clinical trials. Following a period as Associate Director Clinical Pharmacology at Janssen (Johnson & Johnson), he returned SGS Life Sciences Services as Medical Director of the clinical pharmacology unit in Antwerp, Belgium. During his time at SGS Steven was responsible for the medical, scientific and operational aspects of the early phase clinical research, leading a team of 7 Investigators. Steven graduated as a Medical Doctor in 1998 and between 1998 and 2001 was medical resident at the Department of Anesthesiology-Reanimation at the University Hospitals of Leuven, Belgium.